Filing Flows › Coherus Oncology (CHRS) › Q2 2026
Coherus Oncology (CHRS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Coherus Oncology (CHRS) reported revenue of $14.3M for the second quarter 2026 (Q2 2026), +40% from a year earlier and +16% from the quarter before. Operating margin was -226.0%, net loss $20.6M (144.2% of revenue).
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.3M | +16% | +40% |
| Operating profit | −$32.3M | — | — |
| Net earnings | −$20.6M | — | -107% |
| Operating cash flow | −$62.1M | — | — |
What changed
Revenue was $14.3M in Q2 2026, up 40% year over year and up 16% from the previous quarter. Toripalimab was the largest line at 95% of revenue. Toripalimab added $3.7M year over year (up 37%), 90% of the total change.
Operating costs exceeded revenue by $32.3M, an operating margin of -226.0%. Total costs fell 16% while revenue rose 40%. The fastest-growing cost line was Cost of revenue (+25%). The quarter ended with a net loss of $20.6M, narrower than the previous quarter's $38.3M loss.
Operating cash flow was −$62.1M. Non-cash charges added back $862K of depreciation and amortization and $2.6M of share-based compensation. Working capital and other items used $44.9M.
Questions
What was Coherus Oncology's revenue in the second quarter 2026?
Coherus Oncology (CHRS) reported revenue of $14.3M for the second quarter 2026 (Q2 2026), +40% from a year earlier and +16% from the quarter before.
Was Coherus Oncology profitable in the second quarter 2026?
Operating loss was $32.3M (-226.0% of revenue) and net loss $20.6M.
Source: Coherus Oncology 10-Q on SEC EDGAR.